PHARMACY

Kryptiq acquires Secure Network Solutions

BY Alaric DeArment

PORTLAND, Ore. Kryptiq, an electronic medical records company, has acquired Secure Network Solutions, Kryptic announced Tuesday.

Secure Network Solutions brings key administrative workflows to Kryptiq’s Connect IQ Platform, including automated appointed reminders, waitlist management and electronic billing statements.

“Our products have dramatically improved operational efficiency and revenue for our customers,” Secure Network Solutions President Ken Ostrowski said. “Kryptiq has the most robust, far-reaching and widely deployed connectivity platform, and working with Kryptiq will enable us to increase the strength of our solutions throughout the health-care IT market.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

States come out against FDA pre-emption rule in Wyeth case

BY Alaric DeArment

MONTPELIER, Vt. Forty-seven states—including Vermont—want the United States Supreme Court to uphold a ruling against Wyeth that forced the drug maker to pay $6.8 million in damages after one of its drugs caused complications requiring a woman’s arm to be amputated.

The woman, Diana Levine of Marshfield, Vt., received an injection of the anti-nausea drug Phenergan in an artery in 2000. The injection caused artery damage and gangrene that eventually required amputation of her right arm. The jury in a lower court awarded Levine, a musician, $6.8 million.

The case will be argued before the Supreme Court Nov. 3.

Wyeth says it won approval for the drug’s warning label from the Food and Drug Administration, and thus should not have been subject to a lawsuit.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA warns of Byetta risk for severe pancreatitis

BY Alaric DeArment

WASHINGTON The Food and Drug Administration has received six reports of hemorrhagic or necrotizing pancreatitis in patients taking Eli Lilly’s Byetta, an injected drug used for treating Type 2 diabetes and known generically as exenatide.

All six cases required hospitalization, and two patients died. At the time of reporting, four were recovering.

The FDA warns that patients should discontinue medication use if pancreatitis is suspected, and that there are no signs to distinguish acute hemorrhagic or necrotizing pancreatitis associated with Byetta from less severe forms of the disease.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?